FDA has authorized Hope Biosciences’ adipose-derived mesenchymal stem cells (HB-adMSCs) for use in the first pediatric clinical trial, to evaluate if intravenous infusion affects signs and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback